Form 4: BDX Executive Sells Shares Under Pre-Arranged 10b5-1 Plan

Becton Dickinson & Co. EVP Michael David Garrison sold 629 shares of common stock for $196.03 per share under a Rule 10b5-1 plan.

Summary

• Michael David Garrison, EVP & President of Medical Essential & BioPharm at Becton Dickinson & Co. (BDX), reported a sale of common stock.
• The transaction involved the disposition of 629 shares of BDX common stock.
• The shares were sold at a price of $196.03 per share.
• Following this transaction, Michael David Garrison beneficially owns 13,105 shares of BDX common stock.
• The sale was executed on December 17, 2025, pursuant to a Rule 10b5-1 plan adopted on August 13, 2025.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, indicating a routine financial management activity rather than a reaction to new material information. Therefore, it carries a neutral sentiment regarding the company's immediate prospects.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction for an executive at a major medical technology company. Such pre-arranged sales under Rule 10b5-1 plans are common for executives to manage personal finances and diversify holdings without being accused of trading on inside information.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in executive ownership, which is generally not considered a significant event given it's a pre-planned transaction.

Key Dates

Keywords

Becton Dickinson, BDX, Insider Sale, Form 4, 10b5-1 Plan, Executive Compensation, Medical Technology